Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PharmaTher Holdings Ltd. (PHRM.CN)
Toronto, ON, CA
PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration techniques for psychedelics to treat a range of conditions including mental health disorders, neurological ailments, and chronic pain. A key asset in its development portfolio is an intravenous ketamine injection, currently undergoing Phase II and III clinical evaluations targeting indications such as Parkinson's disease, anesthesia/sedation, and amyotrophic lateral sclerosis (ALS). The company's pipeline further features a Ketamine Patch, which is progressing through Phase I and II clinical trials for the treatment of depression, various mental health conditions, complex regional pain syndrome (CRPS), and other pain-related disorders. Additionally, a Ketamine Pump is undergoing Phase II clinical assessment for use in mental health, pain management, and surgical/procedural settings. Beyond these, PharmaTher is actively developing PHARMAPATCH, an innovative microneedle patch designed for psychedelic drug delivery. The company has established strategic collaboration agreements with several partners, including LTS Lohmann Therapie-Systeme AG for developing a ketamine microneedle patch; Alcami Corporation for the advancement of ketamine injectables and infusions; BioRAE, Inc. for the development of ketamine pump technology; Revive Therapeutics Ltd. to develop a psilocybin microneedle patch; and Gesval S.A. for the development of patented continuous-flow process technology for synthesizing ketamine and its analogs. PharmaTher is also internally dedicated to creating its own proprietary wearable ketamine delivery system, intended for addressing mental health, neurological, and pain conditions. Established in 2019, the company maintains its headquarters in Toronto, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +13.33% | +6.25% | +30.77% | -5.56% | -29.17% | -19.05% | -61.36% | -32.00% | -60.47% | -60.47% | -60.47% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+51.3% ★ Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +259.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.3% ★ Q1'26: +2.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
May 2025 actual |
May 2026 1 Rev. Ana. 1 EPS Ana. |
May 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
—
|
27.60M
27.60M – 27.60M
|
83.60M
83.60M – 83.60M
+202.9% YoY
|
| EBITDA |
-1.52M
|
—
— – —
|
—
— – —
|
| EBIT |
-1.52M
|
—
— – —
|
—
— – —
|
| Net Income |
-1.53M
est: -8.85M (+82.8%)
|
-7.08M
-7.08M – -7.08M
+20.0% YoY
|
-3.54M
-3.54M – -3.54M
+50.0% YoY
|
| SGA |
942.1K
|
—
— – —
|
—
— – —
|
| EPS |
-0.02
est: -0.10 (+82.8%)
|
-0.08
-0.08 – -0.08
+20.0% YoY
|
-0.04
-0.04 – -0.04
+50.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fabio Chianelli | Founder, Chairman & Chief Executive Officer | 360.0K | male |
| Carmelo Marrelli ACIS | Chief Financial Officer | 80.2K | male |
| Andrew Todd | Corporate Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHRM.CN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
